Interferon α. biology, pharmacology and therapy for chronic viral hepatitis.

The Cytokine Handbook

Volumn , Issue , 2003, Pages 1233-1254

  Dusheiko, Geoffrey M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 10044234511     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50058-2     Document Type: Chapter

References (105)

1. EASL International Conference on hepatitis C. Consensus statements. J. Hepatol. 1999, 30:956-961.
2. Aebi M., Fah J., Hurt N., et al. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol. Cell Biol. 1989, 9:5062-5072.
3. Alter M.J., Margolis H.S., Krawczynski K., et al. The natural history of community-acquired hepatitic C in the United States. N. Engl. J. Med. 1992, 327:1899-1905.
4. Antonelli G., Currenti M., Turriziani O., et al. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-α preparations. J. Infect. Dis. 1991, 163:882-885.
5. Bianchi L., Zimmerli-Ning M., Gudat F. Viral hepatitis. Pathology of the liver 1979, 164-191. Churchill Livingstone, Edinburgh. R. MacSween, P. Anthony, P. Scheuer (Eds.).
6. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 2001, 75:7059-7066.
7. Bodsworth N., Donovan B., Nightingale B.N. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J. Infect. Dis. 1989, 160:577-582.
8. Brook M.G., Petrovic L., McDonald J.A., et al. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J. Hepatol. 1989, 8:218-225.
9. Brunetto M.R., Oliveri F., Rocca G., et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989, 10:198-202.
10. Caselmann W.H., Eisenburg J., Hofschneider P.H., Koshy R. Beta- and gamma-interferon in chronic active hepatitis B. A pipot trial of short-term combination therapy. Gastroenterology 1989, 96:449-455.
11. Cavanaugh V.J., Guidotti L.G., Chisari F.V. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J. Virol. 1998, 72:2630-2637.
12. Chang C.H., Fontes J.D., Peterlin M., Flavell R.A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 1994, 180:1367-1374.
13. Chang Y.E., Laimins L.A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 2000, 74:4174-4182.
14. Chien R.N., Liaw Y.F., Chen T.C., et al. Efficiacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology 1998, 27:1383-1387.
15. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
16. Cohen B., Peretz D., Vaiman D., et al. Enhancer-like interferon responsive sequences of the humane murine (2'-5') oligoadenylate synthetase gene promoters. EMBO J. 1998, 7:1411-1419.
17. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 1989, 321:1501-1506.
18. Deonarain R., Alcami A., Alexiou M., et al. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J. Virol. 2000, 74:3404-3409.
19. Der S.D., Zhou A., Williams B.R., Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci USA 1998, 95:15623-15628.
20. Di-Bisceglie A.M., Rustigi V.K., Kassianides C., et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990, 11:266-270.
21. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112S-121S.
22. Dusheiko G., Dibisceglie A., Bowyer, et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 1985, 5:556-560.
23. Dusheiko G.M., Paterson A.C., Pitcher L., et al. Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials. J. Hepatol. 1986, 3:S199-S207.
24. Fattovich G., Farci P., Rugge M., et al. A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992, 15:584-589.
25. Feinstone S.M., Kapikian A.Z., Purcell R.H., et al. Transfusion associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 1975, 292:767-770.
26. Frese M., Pietschmann T., Moradpour D., et al. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 2001, 82:723-733.
27. Fried M.W. Advances in therapy for chronic hepatitis C. Clin Liver Dis 2001, 4:1009-1023.
28. Galibert F., Mandart E., Fitoussi F., et al. Neucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979, 281:646-650.
29. Garcia de Ancos J.L., Roberts D.A., Dusheiko G.M. An economic evaluation of the costs of α interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J. Hepatol. 1990, 11:s111-s118.
30. Glue P., Rouzier-Panis R., Raffanel C., et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000, 32:647-653.
31. Goodbourn S. The regulation of beta-interferon gene expression. Semin. Cancer Biol. 1990, 1:89-95.
32. Guidotti L.G., Ando K., Hobbs M.V., et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA 1994, 91:3764-3768.
33. Guidotti L.G., Rochford R., Chung J., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
34. Guilhot S., Guidotti L.G., Chisari F.V. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a postranscriptional mechanism. J. Virol. 1993, 67:7444-7449.
35. Haller O., Frese M., Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev. Sci. Tech. 1998, 17:220-230.
36. Harada H., Fujita T., Miyamoto M., et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989, 58:729-739.
37. Heathcote J., Kim Y.I., Yim C.K., et al. Interferon-associated lymphocyte 2'5'-oligoadenylate synthetase in acute and chronic viral hepatitis. Hepatology 1989, 9:105-109.
38. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000, 343:1673-1680.
39. Hoofnagle J.H. Chronic hepatitis B. N. Engl. J. Med. 1990, 323:337-339.
40. Hoofnagle J.H. Chronic hepatitis B (editorial, comment). N. Engl. J. Med. 1990, 323:337-339.
41. Hoofnagle J.H. Therapy for acute hepatitis C. N. Engl. J. Med. 2001, 345:1495-1497.
42. Hsu H.-Y., Chang M.-H., Hsieh K.-H., et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992, 15:770-776.
43. Isaacs A., Lindenmann J. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann. J. interferon Res. 1957, 7:429-438.
44. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001, 345:1452-1457.
45. Jen J.F., Glue P., Ezzet F., et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther. 2001, 69:407-421.
46. Jung V., Rashidbaigi A., Jones C., et al. Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma. Proc. Natl Acad. Sci. USA 1987, 84:4151-4155.
47. Kaneko S., Miller R.H., Feinstone S.M., et al. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc. Natl. Acad. Sci. USA 1989, 86:312-316.
48. Kerr I.M. The 2-5A system: a personal view. J. Interferon 1987, 7:505-510.
49. Khakoo S., Glue P., Grellier L., et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 1998, 46:563-570.
50. Korenman J., Baker B., Waggoner J., et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991, 114:629-634.
51. Kosaka Y., Takase K., Kojima M., et al. Fulminant hepatitis B: Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991, 100:1087-1094.
52. Kuo G., Choo Q.L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244:362-364.
53. Kuo C.H., Changchien C.S., Yang C.Y., et al. Bacteremia in patients with cirrhosis of the liver. Liver 1991, 11:334-339.
54. Lai M.M.C. The molecular biology of hepatitis delta virus. Ann. Rev. Biochem. 1995, 64:259-286.
55. Lau J.Y.N., Lai C.L., Wu P.C., et al. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J. Med. Virol. 1991, 34:184-187.
56. Lau J.Y.N., Bain V.G., Davies S.E., et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992, 102:956-962.
57. Lee C.K., Gimeno R., Levy D.E. Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes. J. Exp. Med. 1999, 190:1451-1464.
58. Levin S., Leibowitz E., Torten J., Hahn T. Interferon treatment in acute progressive and fulminant hepatitis. Israel J. Med. Sci. 1989, 25:364-372.
59. Liang T.J., Hasegawa K., Rimon N., et al. A hepatitis B mutant associated with an epidemic of fulminant hepatitis. N. Engl. J. Med. 1991, 324:1705-1709.
60. Lisker-Melman M., Webb D., Di-Bisceglie A.M., et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann. Intern. Med. 1989, 111:479-483.
61. Lok A.S., Lai C.L., Wu P.C., et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin. Liver Dis. 1989, 9:249-253.
62. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001, 120:1828-1853.
63. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
64. Marcellin P., Loriot M.A., Boyer N., et al. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 1990, 12:155-158.
65. Marcellin P., Martinot-Peignoux M., Loriot M.A., et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Ann. Intern. Med. 1990, 112:227-228.
66. Marie I., Durbin J.E., Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 1998, 17:6660-6669.
67. McNair A.N.B., Kerr I.M. Viral inhibition of the interferon system. Pharmacol. Ther. 1992, 56:79-95.
68. Meurs E., Chong K., Galabru J., et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990, 62:379-390.
69. Michel T., Feron O. Nitric oxide synthases: which, where, how, and why?. J. Clin. Invest. 1997, 100:2146-2152.
70. Milich D.R., Jones J.E., Hughes J.L., et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero. Proc. Natl Acad. Sci. USA 1990, 87:6599-6603.
71. Mishiro S., Hoshi Y., Takeda K., et al. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet 1990, 336:1400-1403.
72. Mutchnick M.G., Appelman H.D., Chung H.T., et al. Thymosin treatment of chronic hepatitis B: A placebocontrolled pilot trial. Hepatology 1991, 14:409-415.
73. Nakao K., Nakata K., Yamashita M., et al. p48 (ISGF-3gamma) is involved in interferon-α-induced suppression of hepatitis B virus enhancer-1 activity. J. Biol. Chem. 1999, 274:28075-28078.
74. Nathan C. Inducible nitric oxide synthase: what difference does it make?. J. Clin. Invest. 1997, 100:2417-2423.
75. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
76. Neumann A.U., Lam N.P., Dahari H., et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 2000, 182:28-35.
77. Omata M., Yokosuka O., Takano S., et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991, 338:914-915.
78. Onji M., Lever A.M., Saito I., Thomas H.C. Defective response to interferons in cells transfected with the hepatitis B virus genome. Hepatology 1989, 9:92-96.
79. Ou J., Laub O., Rutter W. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl Acad. Sci. USA 1986, 83:1578-1582.
80. Patterson J.B., Samuel C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adneosine deaminase from human cells: evidence for two forms of the deaminas. Mol. Cell Biol. 1995, 15:5376-5388.
81. Polyak S.J., Paschal D.M., McArdle S., et al. Characterization of the effects of hepatitis C virus non-structural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999, 29:1262-1271.
82. Quiroga J.A., Mora I., Porres J.C., Carreno V. Elevation of 2',5'-oligoadenylate synthetases activity and HLA-I associated beta 2-microglobulin in response to recombinant interferon-gamma administration in chronic HBeAg-positive hepatitis. J. Interferon Res. 1988, 8:755-763.
83. Rakela J., Wood J.R., Czaja A.J., et al. Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: A prospective, randomized treatment trial. Mayo Clin. Proc. 1990, 65:1330-1335.
84. Rashidbaigi A., Langer J.A., Jung V., et al. The gene for the human immune interferon receptor is located on chromosome 6. Proc. Natl Acad. Sci. USA 1986, 83:384-388.
85. Reddy K.R., Wright T.L., Pockros P.J., et al. Efficacy and safety of peglylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001, 33:433-438.
86. Rizzetto M., Rosina F., Saracco G., et al. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. J. Hepatol. 1986, 2:S229-S233.
87. Rosina F., Pintus C., Meschievitz C., Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-α in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology 1991, 13:1052-1056.
88. Ruiz-Moreno M., Jimenez J., Porres J.C., et al. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990, 45:26-33.
89. Rutherford M.N., Hannigan G.E., Williams B.R.G. Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J. 1988, 7:751-759.
90. Ryff J.-C. To treat or not to treat? The judicious use of interferon-α-2a for the treatment of chronic hepatitis B. J. Hepatol. 1993, 17:S42-S46.
91. Samuel C.E. Mechanisms of interferon action: phosphorylation of protein synthesis initiation factor eIF2 in interferon-treated human cells by a ribosome associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc. Natl Acad. Sci. USA 1979, 76:600-604.
92. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809.
93. Siddiqui A., Jameel S., Mapoles J. Transcriptional control elements of hepatitis B surface antigen gene. Proc. Natl Acad. Sci. USA 1986, 83:566-570.
94. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
95. Stahl S., MacKay P., Magazin M., et al. Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis. Proc. Natl Acad. Sci. USA 1982, 79:1606-1610.
96. Steimle V., Siegrist C.A., Motter A., et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994, 265:106-109.
97. Tan S.L., Nakao H., He Y.P., et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/liganling. Proc. Natl Acad. Sci. USA 1999, 96:5533-5538.
98. Taylor D.R., Shi S.T., Romano P.R., et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
99. Thomis D.C., Doohan J.P., Samuel C.E. Mechanism of interferon action: cDNA structure, expression, and regulation of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from human cells. Virology 1992, 188:33-46.
100. Tough D.F., Kamath A.T. Interferon with dendritic cells?. Nat. Immunol. 2001, 2:1098-1100.
101. Twu J.S., Lee C.H., Lin P.M., Schloemer R.H. Hepatitis B virus suppresses expression of human betainterferon. Proc. Natl Acad. Sci. USA 1988, 85:252-256.
102. Wang Y., Zeng Y., Murray J.M., Nishikura K. Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing. J. Molec. Biol. 1995, 254:184-195.
103. Williams B.R.G., Kerr I.M. Inhibition of protein synthesis by 2'-5' linked adenine oligonucleotides in intact cells. Nature 1978, 276:88-89.
104. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000, 343:1666-1672.
105. Zhou A., Hassel B.A., Silverman R.H. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 1993, 72:753-765.